# IKS04 Regimen in Advanced Solid Tumors That Express CA242

> **NCT07738939** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Iksuda Therapeutics Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Colorectal Cancer
- Gastro Esophageal Junctional Cancer
- Gastric Cancer (GC)
- GEJ Adenocarcinoma
- PDAC - Pancreatic Ductal Adenocarcinoma
- Biliary Tract Cancer (BTC)
- Gall Bladder Cancer
- Cholangiocarcinoma

## Interventions

- **DRUG:** IKS04 antibody drug conjugate ADC + Isumab04 monoclonal antibody

## Key facts

- **NCT ID:** NCT07738939
- **Lead sponsor:** Iksuda Therapeutics Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-11
- **Primary completion:** 2028-12
- **Final completion:** 2029-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07738939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07738939, "IKS04 Regimen in Advanced Solid Tumors That Express CA242". Retrieved via MORVS 2026-10-22 from https://api.morvs.ai/clinical/NCT07738939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*